Subscribe
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Breast Cancer-OFS Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Articles
Breast Cancer Survivors with Functional Limitations Have Poor Prognosis
Hematologic Cancers
TON - Daily
Women who have difficulty performing normal activities of daily living after an initial treatment for breast cancer have reduced overall survival compared with survivors without functional limitations, results of a long-term study indicate.
“Our study provides evidence of why it is important to develop interventions that improve physical function, to mitigate the adverse effects of physical limitations,” said lead author Dejana Braithwaite, PhD, of the University of California San Francisco.
In the study published online in
The Journal of the National Cancer Institute, s
he and her associates studied the long-term prognostic role of functional limitations in a cohort of 2202 women who participated in the Life After Cancer Epidemiology study. The women provided information on body functions involving endurance, strength, muscular range of motion, and small muscle dexterity after initial adjuvant therapy.
The majority of the women were early-stage breast cancer survivors, and their median age was 57 years at the time of entrance to the study. Thirty-nine percent of the subjects reported one or more physical limitations at study entry. Older women and those who were overweight or obese had more functional limitations.
During a median follow-up period of 9 years, 112 women died of competing (non-breast cancer) causes and 157 of breast cancer. Multivariate analysis showed that functional limitations increased the risk of death from all causes and from competing causes but not from breast cancer.
The authors advise that adding assessment of functional status to clinical screening of breast cancer patients may help to identify groups that are at high risk of poor prognosis, which would allow “targeting of functionally impaired patients to improve quality and length of life.”
Related Items
Axicabtagene Ciloleucel Induces Durable Responses in Advanced Follicular Lymphoma and Marginal-Zone Lymphoma
By
William King
TON - August 2020, Vol 13, No 4
Hematologic Cancers
CAR T-Cell Therapy Shows Highly Durable Remissions in CLL and B-Cell Lymphoma
By
Charlie Dawson
TON - August 2020, Vol 13, No 4
Hematologic Cancers
November 4, 2019 — Oncology News & Updates
Web Exclusives
Financial Toxicity
,
Head and Neck Cancer
,
Hematologic Cancers
,
In the News
,
Leukemia
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1
Conference Correspondent
,
ASH
,
Palliative Care
,
Hematologic Cancers
Educating Your Patients About Daratumumab
By
Leslie Lauersdorf, ARNP
Conference Correspondent
Hematologic Cancers
,
Conference Correspondent
,
ASH
How to Handle Survivorship Care for Multiple Myeloma
By
Tiffany Richards, PhD, ANP-BC
Conference Correspondent
Hematologic Cancers
,
Conference Correspondent
,
ASH
How to Utilize New Mutliple Myeloma Drugs
By
Tiffany Richards, PhD, ANP-BC
Conference Correspondent
Hematologic Cancers
,
Conference Correspondent
,
ASH
Preparing Your Patients for Side Effects
By
Tiffany Richards, PhD, ANP-BC
Conference Correspondent
Hematologic Cancers
,
Conference Correspondent
,
ASH
Know Your Patients' Baselines
By
Tiffany Richards, PhD, ANP-BC
Conference Correspondent
Hematologic Cancers
,
Conference Correspondent
,
ASH
Meeting the Needs of the Patient
By
Tiffany Richards, PhD, ANP-BC
Conference Correspondent
Hematologic Cancers
,
Conference Correspondent
,
ASH
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Breast Cancer-OFS Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION